Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
I'd use it with patients
3 It was approved by the US FDA in 2023 to treat obesity (Zepbound , Eli Lilly and Company, Indianapolis, IN, USA) which was initially approved to treat type 2 diabetes in 2022 (Mounjaro , Eli Lilly and Company) (Table 1)
This suggests that the underlying driver of improved CV outcomes with semaglutide extends beyond simple reduction in obesity and perhaps indicates a direct effect on vasculature and reduction in atherosclerosis, although this remains unproven
Often improves within several weeks without intervention
US$ 23.73
US$ 22.08
US$ 23.73
